Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Edgewise Therapeutics

Request full access

A new biotech company harnessing proven expertise and understanding of skeletal muscle

Boulder, United StatesFounded 2017Biotech & Life Sciences

About Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company focused on developing innovative therapies for rare muscle disorders such as Duchenne, Becker, and Limb Girdle muscular dystrophies, as well as McArdle disease. Utilizing a proprietary drug discovery platform, the company aims to create a holistic therapeutic approach to protect muscle health. Edgewise Therapeutics serves patients and families affected by these progressive muscle disorders, operating within the niche market of precision medicine for rare diseases. The business model involves retaining global development and commercialization rights to its programs, allowing for strategic collaborations and asset acquisitions to accelerate development and expand its pipeline. Revenue is generated through the development and commercialization of its lead molecule, sevasemten (EDG 5506), which targets the muscle motor protein myosin to reduce stress in fast skeletal muscle fibers without affecting other muscle types.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Edgewise Therapeutics in the Boulder ecosystem

Live from Dealroom

The Edgewise Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later17 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$11M

14 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Edgewise Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.